# A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

> **NCT04552977** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 50 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** fluzoparil
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT04552977
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2021-08
- **Final completion:** 2022-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552977, "A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04552977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*